# US 7,745,139 B1 · Peptides of the AT1 receptor and their uses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,139 B1
- Document ID: US7745139B1
- Status: Granted
- Kind: B1
- Application number: 09/868,967
- Filed: 1999-12-22
- Granted: 2010-06-29
- Earliest claimed: 1998-12-24
- Assignees: Max-Delbruck-Centrum fur Molekulare Medizin
- Inventors: Gerd Wallukat; Volker Homuth; Friedrich Luft
- Web page: https://patentgrep.com/patent/US7745139B1

## CPC

- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/70571: {for neuromediators, e.g. serotonin receptor, dopamine receptor}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed are peptides of the AT1 receptor and their use for eliminating specifically binding, cell-physiologically active, pathological antibodies in preeclampsia and malign hypertension. The peptides may, for example, be used for the diagnosis of preeclampsia. Peptides having the sequence AFHYESQ (SEQ ID NO: 1), AVHYQSN (SEQ ID NO: 2), SHFYQTR (SEQ ID NO: 3), GYYFDTN (SEQ ID NO: 4) or ENTNIT (SEQ ID NO: 5) are preferred.

## Claims

### Claim 1

A method for binding auto-antibodies comprising:
providing isolated peptides of an AT1 receptor consisting essentially of at least one of amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, wherein said peptides bind auto-antibodies occurring in patients with preeclampsia,
contacting said peptides in vitro with a blood sample from a patient suspected of having preeclampsia under conditions permitting binding of said auto-antibodies with said peptide, and
binding said auto-antibodies in said blood sample via said peptides, wherein preeclampsia is diagnosed via said binding.

### Claim 2 (depends on 1)

The method of claim 1, wherein said peptides are soluble or bound to a solid phase and wherein the method comprises a direct or indirect detection of said auto-antibodies in the blood sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the blood sample is plasma or serum sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptides are bound to a solid phase and wherein the method further comprises neutralizing said auto-antibodies via said peptides.

### Claim 5 (depends on 4)

The method of claim 4, wherein said blood sample is maternal blood.

### Claim 6 (depends on 4)

The method of claim 4, wherein said solid phase is part of a column.

### Claim 7

A method of binding auto-antibodies against the angiotensin AT1 receptor in a blood sample in vitro comprising contacting an isolated peptide of the AT1 receptor with a body fluid under conditions permitting binding of said auto-antibodies with said peptide, wherein the peptide consists essentially of the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, or SEQ ID NO:4.

### Claim 8 (depends on 7)

The method of claim 7, wherein the peptide consists essentially of the amino acid sequence of SEQ ID NO:1.

### Claim 9 (depends on 7)

The method of claim 7, wherein said blood sample is maternal blood.

### Claim 10 (depends on 7)

The method of claim 7, further comprising detecting said auto-antibodies in said blood sample.

### Claim 11 (depends on 7)

The method of claim 7, wherein the blood sample is plasma or serum sample.

### Claim 12

A method of binding auto-antibodies against the angiotensin AT1 receptor in maternal blood in vitro comprising contacting an isolated peptide of the AT1 receptor with the maternal blood under conditions permitting binding of said auto-antibodies with said peptide, wherein the Peptide consists essentially of the amino acid sequence of SEQ ID NO: 1.